Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1650175DOI Listing

Publication Analysis

Top Keywords

response trametinib
4
trametinib histiocytosis
4
histiocytosis activating
4
activating mutation
4
response
1
histiocytosis
1
activating
1
mutation
1

Similar Publications

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within preexisting benign lesions called plexiform neurofibromas (PNs). PNs are solely driven by biallelic loss eliciting RAS pathway activation, and they respond favorably to MEK inhibitor therapy.

View Article and Find Full Text PDF

Background: Predictive, preventive, and personalized medicine (PPPM/3PM) is a strategy aimed at improving the prognosis of cancer, and programmed cell death (PCD) is increasingly recognized as a potential target in cancer therapy and prognosis. However, a PCD-based predictive model for serous ovarian carcinoma (SOC) is lacking. In the present study, we aimed to establish a cell death index (CDI)-based model using PCD-related genes.

View Article and Find Full Text PDF

Cutaneous malignant melanoma (MM) is the most aggressive form of skin cancer, associated with high mortality and rising incidence rates in Europe despite prevention efforts. Nodular MM, the most aggressive subtype, often mimics other skin tumors, complicating diagnosis. We present the case of a 66-year-old woman with a large, ulcerated tumor beneath the left scapula, along with multiple nodular lesions on the left arm and chest.

View Article and Find Full Text PDF
Article Synopsis
  • A 73-year-old man with worsening shortness of breath and respiratory failure was diagnosed with primary lung adenocarcinoma featuring the BRAF V600E mutation after imaging and biopsy.
  • He started treatment with a combination of dabrafenib and trametinib, which led to significant clinical and radiological improvements while being well-tolerated despite his critical condition.
  • This case highlights the potential effectiveness and safety of targeted therapies for patients with serious health challenges, such as acute respiratory failure and poor performance status, in the context of BRAF V600E mutated non-small cell lung cancer.
View Article and Find Full Text PDF

A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!